Evaluation of the modulation of P-glycoprotein (P-gp) on the intraocular disposition of its substrate in rabbits

Current Eye Research

Volumn 33, Issue 4, 2008, Pages 333-343

  Senthilkumari, Srinivasan ^a   Velpandian, Thirumurthy ^a,b   Biswas, Nihar Ranjan ^a   Saxena, Rohit ^a   Ghose, Supriyo ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Intravitreal kinetics; Microdialysis and rabbits; P glycoprotein; Rhodamine 123

Indexed keywords

ELACRIDAR; GLYCOPROTEIN P; RHODAMINE 123; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD RETINA BARRIER; CHOROID; CONTROLLED STUDY; CORNEA; DRUG DISPOSITION; DRUG DISTRIBUTION; ENUCLEATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IRIS; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RABBIT; TISSUE DISTRIBUTION; VITREOUS BODY;

ACRIDINES; ANIMALS; BLOOD-BRAIN BARRIER; CARRIER PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EYE; FLUORESCENT DYES; INJECTIONS; INJECTIONS, INTRAVENOUS; KINETICS; MALE; MICRODIALYSIS; P-GLYCOPROTEIN; RABBITS; RETINA; RHODAMINE 123; RIFAMPIN; TETRAHYDROISOQUINOLINES; TISSUE DISTRIBUTION; VITREOUS BODY;

EID: 41949133899     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680802015720     Document Type: Article

References (31)

1. Ambudkar SV, Dey S, Hryeyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361-398.
2. Cunha-Vaz JG. The blood-retinal barriers. Doc Ophthalmol. 1976;41:287-327.
3. Kennedy BG, Mangini NJ. P-glycoprotein expression in human retinal pigment epithelium. Mol Vis. 2002;8:422-430.
4. Holash JA, Steward PA. The relationship of astrocyte-like cells to the vessels that contribute to the blood-ocular barriers. Brain Res. 1993;629:218-224.
5. Cunha-Vaz JG. Blood-retinal barriers in health and disease. Trans Ophthalmol Soc UK. 1980;100:337-340.
6. Schinkel AH, Wagenaar E, Mol CA, Van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996;97:2517-2524.
7. Chen C, Pollack GM. Enhanced antinociception of the model opioid peptide [D-pencillamine 2.5] enkephalin by P-glycoprotein modulation. Pharm Res. 1999;16:296-301.
8. Senthilkumari S, Velpandian T, Biswas NR, Sonali N, Ghose S. Evaluation of the impact of P-glycoprotein (P-gp) drug efflux transporter blockade on the systemic and ocular disposition of P-gp substrate. J Ocul Pharmacol Ther. 2007 (In Press).
9. Abel R, Boyle GL. Dissecting ocular tissue for intraocular drug studies. Invest Ophthalmol Vis Sci. 1976;15:216-219.
10. Lopez-Cortes LF, Pastor-Ramos MT, Ruiz-Valderas R, Cordero E, Uceda-Montanes A, Claro-Cala CM, Lucero-Munoz MJ. Intravitreal pharmacokinetics of retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2001;42:1024-1028.
11. Ito A, Yamaguchi K, Onogawa T, Unno M, Suzuki T, Nishio T, Sasano H, Abe T, Tamai M. Distribution of organic anion-transporting polypeptide 2 (oatp2) and oatp3 in rat retina. Invest Ophthalmol Vis Sci. 2002;43:858-863.
12. Hosoya K, Tomi M. Advances in the cell biology of transport via the inner blood-retinal barrier: Establishment of cell lines and transport functions. Biol Pharm Bull. 2005;28:1-8.
13. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: Emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006; 58:1136-1163.
14. Duvvuri S, Gandhi MD, Mitra AK. Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. Curr Eye Res. 2003;27:345-353.
15. Yumoto R., Murakami T, Nakamoto Y. Transport of Rhodamine-123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther. 1999;289:149-155.
16. Wang Q, Yang H, Miller DW, Elmquist WF. Effect of the P-glycoprotein inhibitor, cyclosporin A, on the distribution of Rhodamine-123 to the brain: An in vivo microdialysis study in freely moving rats. Biochem Biophys Res Commun. 1995;211:719-729.
17. Kajikawa T, Mishima HK, Murakami T, Takano M. Role of P-glycoprotein in distribution of Rhodomine-123 into aqueous humor in rabbits. Current Eye Res. 1999;18:240-246.
18. Pavek P, Staud F, Fendrich Z. Examination of the functional activity of P-glycoprotein in the rat placental barrier using Rhodamine-123. J Pharmacol Exp Ther. 2003;305:1239-1250.
19. Dogan AL, Legrand O, Faussat AM, Perrot JY, Marie JP. Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines. Leuk Res. 2004;28:619-622.
20. Alqawi O, Bates S, Georges E. Arginine 482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits Rhodamine-123 transport while increasing binding. J Biochem. 2004;382:711-716.
21. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, Von Richter O, Zundler J, Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampicin. J Clin Invest. 1999;104:147-153.
22. Ward KW, Azzarano LM. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10 - dihydro-5-methoxy-9-oxo-N-[4-[ 2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2- isoquinolinyl ) ethyl ]phenyl ]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey. J Pharmacol Exp Ther. 2004;310:703-709.
23. Zhang S, Wang X, Sagawa, K. Morris ME. Flavonoids, chrysin, and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug. Metab. Dispos. 2005;33:341-348.
24. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993;53:4595-4602.
25. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P450 3A coordinately upregulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996;49:311-318.
26. Kageyama M, Fukushima K, Togawa T, Fujimoto K, Taki M, Nishimura A, Ito Y, Sugioka N, Shibata N, Takada K. Relationship between excretion and clearance of Rhodamine-123 and P-gp expression induced by representative P-gp inducers. Biol Pharm Bull. 2006;29:779-784.
27. Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter. Gen Pharmacol. 1996;27:1283-1291.
28. Praksh J, Velpandian T, Pande JN, Gupta SK. Serum rifampicin levels in patients with tuberculosis: Effect of P-glycoprotein and Cyp3A4 blockers on its absorption.Clin Drug Invest. 2003;23:463-472.
29. Salphati L, Benet LZ. Modulation of P-gp expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol. 1998;55:387-395.
30. Zong J, Pollack GM. Modulation of P-glycoprotein transport activity in the mouse BBB by rifampicin. J Pharmacol Exp Ther. 2003;306:556-562.
31. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276:14581-14587.